Glofitamab and polatuzumab vedotin in DLBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCLПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCLПодробнее

Results of POLARIX Trial #oncology #cancer #2023Подробнее

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.Подробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?Подробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCLПодробнее

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalkПодробнее

Dr. Herrera Discusses Polatuzumab Vedotin in DLBCLПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Phase Ib Polatuzumab Vedotin TrialПодробнее

DLBCL Prognosis & Management in Front-line Settings #oncology #lungcancer #cancer #2023Подробнее